Ardelyx Inc (ARDX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Ardelyx Inc stock (ARDX) is currently trading at $5.64. Ardelyx Inc PS ratio (Price-to-Sales) is 3.22. Analyst consensus price target for ARDX is $16.10. WallStSmart rates ARDX as Sell.
- ARDX PE ratio analysis and historical PE chart
- ARDX PS ratio (Price-to-Sales) history and trend
- ARDX intrinsic value — DCF, Graham Number, EPV models
- ARDX stock price prediction 2025 2026 2027 2028 2029 2030
- ARDX fair value vs current price
- ARDX insider transactions and insider buying
- Is ARDX undervalued or overvalued?
- Ardelyx Inc financial analysis — revenue, earnings, cash flow
- ARDX Piotroski F-Score and Altman Z-Score
- ARDX analyst price target and Smart Rating
Ardelyx Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Ardelyx Inc (ARDX) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Ardelyx Inc (ARDX) Key Strengths (1)
69.56% held by institutions, strong professional interest
Supporting Valuation Data
Ardelyx Inc (ARDX) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Company is losing money with a negative profit margin
Near-zero operating margins, business under pressure
Very expensive at 7.8x book value
Modest revenue growth at 7.80%
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 3.22x sales
Supporting Valuation Data
Ardelyx Inc (ARDX) Detailed Analysis Report
Overall Assessment
This company scores 25/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 8.0/10) while 8 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Profit Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (3.22), Price/Book (7.82) suggest expensive pricing. Growth concerns include Revenue Growth at 7.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -36.20%, Operating Margin at 4.07%, Profit Margin at -15.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -36.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 7.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ARDX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ARDX's Price-to-Sales ratio of 3.22x trades at a deep discount to its historical average of 104.31x (3th percentile). The current valuation is 100% below its historical high of 694.34x set in Dec 2019, and 21% above its historical low of 2.67x in May 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Ardelyx Inc (ARDX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Ardelyx Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 407M with 8% growth year-over-year. The company is currently unprofitable, posting a -15.1% profit margin.
Key Findings
Generating 21M in free cash flow and 21M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -15.1% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Debt management: total debt of 212M is significantly higher than cash (68M). Monitor refinancing risk.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Ardelyx Inc.
Bottom Line
Ardelyx Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(50 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:04:26 AM
About Ardelyx Inc(ARDX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.